085660.KQ
Chabiotech Co.,Ltd.
KOE · Healthcare · Biotechnology · KR
KRW 7,920.00
−1.00%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1311.4B | 1268.3B | 1045.0B | 954.0B | 844.6B |
| Cost of Revenue | 968.7B | 943.8B | 769.8B | 677.6B | 655.4B |
| Gross Profit | 342.7B | 324.5B | 275.3B | 276.4B | 189.2B |
| Operating Expenses | |||||
| R&D Expense | 23.6B | 24.6B | 16.0B | 14.6B | 14.4B |
| SG&A Expense | 287.8B | 184.5B | 147.9B | 122.7B | 104.4B |
| General & Admin Expense | 82.1B | 104.2B | 105.9B | 83.5B | 69.6B |
| Selling & Marketing Expense | 44.3B | 80.3B | 41.9B | 39.2B | 34.8B |
| Other Expenses | 106.2B | 172.6B | 171.1B | 148.6B | (10.5B) |
| Total Operating Expenses | 417.6B | 381.6B | 334.9B | 285.9B | 242.8B |
| Cost and Expenses | 1386.2B | 1325.4B | 1104.7B | 963.4B | 898.3B |
| Operating Income (EBIT) | (74.9B) | (57.1B) | (59.7B) | (9.4B) | (53.7B) |
| Non-Operating | |||||
| Interest Income | 12.3B | 11.5B | 10.4B | 16.2B | 6.6B |
| Interest Expense | 53.6B | 54.8B | 37.2B | 2.2B | 20.9B |
| Net Interest Income | (41.4B) | (43.4B) | (26.7B) | 14.0B | (14.3B) |
| Other Non-Op Income/Expense | 78.6B | (86.1B) | 53.5B | 12.6B | (16.9B) |
| Non-Operating Income (excl Interest) | (123.1M) | — | (90.6B) | (41.7B) | (3.2B) |
| EBT (Pre-Tax Income) | 3.7B | (143.3B) | (6.2B) | 3.2B | (70.5B) |
| Income Tax Expense | 20.1B | 3.4B | 8.3B | 8.7B | (1.6B) |
| Bottom Line | |||||
| Net Income | 14.3B | (109.9B) | (8.1B) | (8.4B) | (47.5B) |
| Earnings from Cont. Ops | (16.4B) | (146.7B) | (14.6B) | (8.4B) | (68.9B) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (3.4B) | (109.9B) | (8.1B) | (8.4B) | (47.5B) |
| Per Share | |||||
| Basic EPS | ₩92 | (₩1,637) | (₩133) | (₩150) | (₩845) |
| Diluted EPS | (₩135) | (₩1,637) | (₩144) | (₩148) | (₩845) |
| Revenue Per Share | ₩14,177 | ₩18,895 | ₩18,670 | ₩16,949 | ₩15,010 |
| Shares | |||||
| Basic Shares Outstanding | 92.5M | 67.1M | 56.0M | 56.3M | 56.3M |
| Diluted Shares Outstanding | 100.9M | 67.1M | 59.5M | 57.1M | 56.3M |
| Profitability Metrics | |||||
| EBITDA | (5.5B) | (853.7M) | 76.0B | 70.1B | (17.7B) |
| D&A | 57.3B | 56.3B | 45.0B | 37.8B | 32.8B |
| EBIT | (62.8B) | (57.1B) | 31.0B | 32.3B | (50.4B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026